TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04414475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive Selinexor oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive Selinexor oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive Selinexor oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive Selinexor oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive Dexamethasone oral tablets.
Study: NCT04348097

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activator instrument
Description: activator instrument was placed perpendicular over the identified trigger point and 10 thrusts were delivered, with a rate of one thrust per second
Study: NCT04414475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive Dexamethasone oral tablets.
Study: NCT04348097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activator instrument
Description: activator instrument was placed perpendicular over the identified trigger point and 10 thrusts were delivered, with a rate of one thrust per second
Study: NCT04414475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive Dexamethasone oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive Dexamethasone oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Participants will receive Bortezomib SC injection.
Study: NCT04348097

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dry needle
Description: By wrist flexion and extension movements, the trigger point was needled in different directions and tried to elicit at least one local twitch response during the procedure and patient's familiar referral pain was tried to obtain . Each dry needling procedure lasted 1-2 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry needle
Description: By wrist flexion and extension movements, the trigger point was needled in different directions and tried to elicit at least one local twitch response during the procedure and patient's familiar referral pain was tried to obtain . Each dry needling procedure lasted 1-2 minutes
Study: NCT01433419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Study: NCT03555422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo for selinexor
Description: Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
Study: NCT01788319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lasertrabeculoplasty
Study: NCT00270296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trizivir
Description: 300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/Zidovudine
Description: 150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: 400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: 200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily
Study: NCT04884646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR with Routine physical therapy and Virtual reality
Description: VR group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery with Routine physical therapy
Description: MI group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy
Description: Group A will be given routine physical therapy in 40-min sessions and 20 min of walking and cycling with a short period of rest, every alternate day (3 days per week) for 12 weeks
Study: NCT01153607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1006578
Description: Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1006578
Description: Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1006578
Description: Healthy volunteers for whole body imaging: Single intravenous bolus injection of 190 MBq BAY1006578, whole body PET for evaluation of effective dose, kinetics of BAY1006578 in blood
Study: NCT03629145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live Music Therapy
Description: Investigator will begin play live guitar and voice music.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Recorded Music Therapy
Description: Investigator will play recorded music.
Study: NCT03866356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention group
Description: The women in the intervention group were provided care according to SICP
Study: NCT04168645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Up to 4 sessions of BCBT (depending on length of stay) will be provided. The first session lasts 1.5 hours and subsequent sessions are 1 hour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Up to 4 sessions of BCBT (depending on length of stay) will be provided. The first session lasts 1.5 hours and subsequent sessions are 1 hour.
Study: NCT02309970

Intervention type: DRUG
Intervention: acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran
Description: subject in this group will receive oral treatment with anti platelet drug

Intervention type: DRUG
Intervention: alteplase
Description: subject in this group will receive intravenous tPA

Intervention type: PROCEDURE
Intervention: endovascular
Study: NCT01908712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: ERT, i.v. infusions weekly
Study: NCT01787669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin (Bevacizumab)
Description: Avastin (Bevacizumab) administered intravitreally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozurdex (dexamethasone)
Description: Ozurdex (dexamethasone) given intravitreally
Study: NCT01161576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies
Description: The experimental drug for this second generation study has a genome identical to that used in our previous study and delivers the same gene, but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). The first dose that was given to the first 6 subjects is 9.0x10\^11(900,000,000,000 molecules of the drug) genome copies/subject. In regards to drug administrations, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes (2 locations at 2 depths through each hole), 3 burr holes per hemisphere.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies
Description: The experimental drug for this 2nd generation study has a genome identical to that used in our previous study and delivers the same gene but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). Group B will receive a dose of 2.85x10\^11 genome copies (285,000,000,000 molecules of the drug). In regards to drug administration, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes, 3 burr holes per hemisphere.
Study: NCT00848757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Description: Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population.
Study: NCT02257528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01726075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COLIRIOBCN070660
Description: One drop per eye twice a day during 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop per eye twice a day during 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine
Description: One drop per eye twice a day during 24 months
Study: NCT02761018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Fitness Tracker
Description: will use a fitness tracker but will not be able to see other participant's data

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness Tracker
Description: will use a fitness tracker and will be able to see other member's daily and weekly results
Study: NCT03576339

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Free Gingival Graft
Description: Free gingival graft removal from palate for socket preservation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free Gingival Graft
Description: Free gingival graft removal from palate for socket preservation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Electric stimulation
Description: Simulation of electric stimulation protocol for 120 seconds once a day in five consecutive days. In Sham stimulation non current will be applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Stimulation
Description: Local Electric Stimulation for 120 seconds once a day in five consecutive days.
Study: NCT05304988

Intervention type: OTHER
Intervention: Testing of the EFT
Description: A research committee which composes of a paediatric oncologist, a ward manager, an assistant professor and a research assistant will be set up. The committee will develop specific questions in EFT and design and implement the clinical Then, subject will be invited to fill in a set of questionnaires covering demographic characteristics, EFT items and a numerical rating scale for pain scores. The oncologist will rate the subject with the most appropriate level of physical activity on a 4-point scale.
Study: NCT01100723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cinacalcet, active vitamin D analogue
Description: Patients will have their mineral and bone disorders managed by the computer directed algorithm. Cinacalcet will be dose increased starting at 30 mg/day as indicated by protocol along with active vitamin D based on values of serum calcium, phosphorus and parathyroid hormone.
Study: NCT06069739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided physical activity
Description: To achieve the European guidelines of 150 minutes by week of moderate intensity physical activity, participants randomized to the GPAG condition were prescribed three 60 minutes exercise sessions (five minutes of warm-up and five minutes of cool-down for a total of sixty minutes per session) per week for 12 weeks. Exercise consisted of brisk walking in urban and rural open spaces during which heart rate monitors were worn and participants were instructed to stay within their moderate intensity range. The incentives were different proposals for specific exercises to train the different musculoskeletal areas more comprehensively. Autonomous exercise was monitored offside the sessions through a series of weekly checkpoints.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical activity
Description: Participants randomised to the SPAG performed their usual daily activities and continued with their daily routine.~Both conditions were matched for duration of physical activity. Participants in both conditions were required to attend three on-site sessions by week over 12 weeks that served as checkpoints. Moreover, both conditions were provided with brief healthy lifestyle counseling at baseline.
Study: NCT02257528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02303639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Description: Catheter ablation with an open-irrigated tip ablation catheter and 3D electroanatomical mapping

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug therapy
Description: Amiodarone (or sotalol) for prevention of VT/VF relapses
Study: NCT03159832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR3824
Description: All subjects were given SHR3824 20mg only one time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR3824
Description: All subjects were given SHR3824 20mg only one time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR3824
Description: All subjects were given SHR3824 20mg only one time.
Study: NCT04524689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701 (Tusamitamab ravtansine)
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701 (Tusamitamab ravtansine)
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
Study: NCT00844402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: oral, 10 mg, daily, 48 weeks
Study: NCT04524689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701 (Tusamitamab ravtansine)
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701 (Tusamitamab ravtansine)
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701 (Tusamitamab ravtansine)
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701 (Tusamitamab ravtansine)
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Study: NCT01416077

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluid optimisation
Description: Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised~1. Crystalloid infusion (2,5 ml/kg/t) throughout surgery~2. 3 ml/kg Volulyte (synthetic colloid) is infused during 5 minutes and SV is measured directly before and 5 minutes after. If SV increases more than 10% the dose is repeated until no increase \> 10% is observed. A new dose is given if SV decreases more than 10% from the last value.~3. If despite optimal filling Cardiac Index (CI) is below 2,5 l/min/m2 infusion with dobutamin is started to attain CI \> 2,5.~4. If despite CI \> 2,5 Mean Arterial Pressure \<65 mmHg vasopressor (phenylephrine / norepinephrine) is started until MAP equals or is over 65.
Study: NCT01406314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: Intravenous infusion for approximately 48hours followed by subcutaneous injection
Study: NCT04524689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Study: NCT02016924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Capsules administered once daily according to dosing recommendations per product monograph

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Capsules administered once daily according to dosing recommendations per product monograph

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Capsules administered once daily according to dosing recommendations per product monograph

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Capsules administered once daily according to dosing recommendations per product monograph

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Capsules administered once daily according to dosing recommendations per product monograph

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Capsules administered once daily according to dosing recommendations per product monograph
Study: NCT02258659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study: NCT02016924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Capsules administered once daily according to dosing recommendations per product monograph

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: Tablets administered once daily according to dosing recommendations per product monograph

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: Tablets administered once daily according to dosing recommendations per product monograph

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: Tablets administered once daily according to dosing recommendations per product monograph

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: Tablets administered once daily according to dosing recommendations per product monograph

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Tablets administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Tablets administered orally once daily with food
Study: NCT02258659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV